The present study demonstrated the role of mpMRI guided in-bore biopsy for detection of prostate cancer (PCa). Patients were recruited based on PSA > 4 ng/ml and abnormal DRE. The PCa detection rate between the two groups of patients, namely 25 patients (Group I) who underwent in-bore biopsy and 73 patients (Group II) who underwent TRUS biopsy were compared. The PCa detection rate of in-bore targeted biopsy was 52% compared to 34.3% for TRUS biopsy. Our data also indicated that in-bore MR targeted biopsy significantly increased the detection rate of PCa when compared with the standard 12 core TRUS biopsy.